What Happened? Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 20.7% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' constant currency revenue, EPS, and EBITDA expectations. Its quarterly revenue guidance also outperformed Wall Street's estimates. The key number was a 30% jump in constant currency sales, led by strong growth in the U.S. and a big push overseas, where Omnipod sales rose 36%. Zooming out, we think this was a solid print. The shares closed the day at $310.38, up 20.8% from previous close. Is now the time to buy Insulet? Access our full analysis report here, it’s free. What The Market Is Telling Us Insulet’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. But moves this big are rare even for Insulet and indicate this news significantly impacted the market’s perception of the business. Insulet is up 21.1% since the beginning of the year, and at $311.10 per share, has set a new 52-week high. Investors who bought $1,000 worth of Insulet’s shares 5 years ago would now be looking at an investment worth $1,384. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. View Comments
Why Insulet (PODD) Stock Is Trading Up Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...